Tevfik Noyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tevfik Noyan has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Üner
Yozgat Public Health Laboratory , Yozgat , Türkiye
7 shared publications - Diler Us Altay
Ordu Üniversitesi
7 shared publications - Erdal Benli
Department of Urology, Faculty of Medicine, Ordu University, Ordu, Turkey
6 shared publications - Murat Cihan
Department of Biochemistry, Memorial Şişli Hospital, Istanbul, Türkiye
5 shared publications - Selma Cirrik
Department of Physiology, Faculty of Medicine, Ordu University, Ordu, Türkiye
5 shared publications - Ali Aygun
Ordu University
3 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Caleo
- Vol. 24 (2) , 21-26
Evaluation of Glucose Results Measured by 2 Different Glucometer Brands
Objective: The aim of this study was to retrospectively evaluate the performance of 2 glucometer devices using the accuracy criteria specified in ISO 15197:2015. Methods: Glucose results obtained from Accu-Chek Inform II and Sejoy BG-707 glucometers, which measure according to the glucose dehydrogenase principle, were compared with glucose results obtained from the Cobas 8000 c702 autoanalyzer, which measures using the hexokinase method. Since the minimum number of patients required according to the ISO 15197:2015 protocol is 100, a total of two hundred patients were included using 2 independent samples, with 100 patient results included for each device. Results: When compared with the autoanalyzer, the Passing-Bablok regression equation for the Accu-Chek brand glucometer was y= 4.606 + .965x, and for the Sejoy brand glucometer y= 6.411 + .964x. In the Bland–Altman plot, the mean difference between glucose values compared to the hexokinase method was for the Accu-Check brand glucometer, 1.41 mg/dL (.08 mmol/L), and for the Sejoy brand glucometer, .09 mg/dL (.005 mmol/L). Furthermore, 98% of the Accu-Chek Inform II results and also 98% of the Sejoy BG-707 results met the ISO 15197:2015 accuracy criteria. In addition, all results for both glucometers were located within Zone A of the Consensus Error Grid. Conclusion: The results of the study showed that both glucometer measurement results were appropriate and reliable according to the ISO 15197:2015 guideline criteria, demonstrated strong agreement with autoanalyzer results using the hexokinase method, and revealed no statistically significant difference between glucometer and autoanalyzer measurements.
- 25 August 2026
- Published by Caleo
- Vol. 24 (2) , 21-26
Open AccessEvaluation of Glucose Results Measured by 2 Different Glucometer Brands
Objective: The aim of this study was to retrospectively evaluate the performance of 2 glucometer devices using the accuracy criteria specified in ISO 15197:2015. Methods: Glucose results obtained from Accu-Chek Inform II and Sejoy BG-707 glucometers, which measure according to the glucose dehydrogenase principle, were compared with glucose results obtained from the Cobas 8000 c702 autoanalyzer, which measures using the hexokinase method. Since the minimum number of patients required according to the ISO 15197:2015 protocol is 100, a total of two hundred patients were included using 2 independent samples, with 100 patient results included for each device. Results: When compared with the autoanalyzer, the Passing-Bablok regression equation for the Accu-Chek brand glucometer was y= 4.606 + .965x, and for the Sejoy brand glucometer y= 6.411 + .964x. In the Bland–Altman plot, the mean difference between glucose values compared to the hexokinase method was for the Accu-Check brand glucometer, 1.41 mg/dL (.08 mmol/L), and for the Sejoy brand glucometer, .09 mg/dL (.005 mmol/L). Furthermore, 98% of the Accu-Chek Inform II results and also 98% of the Sejoy BG-707 results met the ISO 15197:2015 accuracy criteria. In addition, all results for both glucometers were located within Zone A of the Consensus Error Grid. Conclusion: The results of the study showed that both glucometer measurement results were appropriate and reliable according to the ISO 15197:2015 guideline criteria, demonstrated strong agreement with autoanalyzer results using the hexokinase method, and revealed no statistically significant difference between glucometer and autoanalyzer measurements.
- Open Access
- 7 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5312
The Effect of COVID-19 Vaccines on Chronic Inflammatory Remodeling in NSTEMI Patients: A Galectin-3-Based Single-Center Study
Background: This study evaluated the potential effects of different COVID-19 vaccine platforms (mRNA and inactivated) on acute coronary syndrome (ACS) through Galectin-3, a biomarker of chronic inflammation and fibrosis. It aimed to compare serum Galectin-3 levels among NSTEMI patients according to COVID-19 vaccination status and vaccine type. Methods: A total of 75 patients with NSTEMI were prospectively enrolled and categorized into three groups: inactivated vaccine recipients (n = 25), mRNA vaccine recipients (n = 25), and unvaccinated controls (n = 25). Serum Galectin-3 levels were measured to assess chronic inflammatory status. Additionally, markers of acute myocardial injury and inflammatory response were analyzed. Results: Galectin-3 levels were similar across the inactivated vaccine, mRNA vaccine, and unvaccinated NSTEMI group, with no statistically significant difference observed (p = 0.481). Although troponin I levels and acute inflammatory cell burden were higher in vaccinated patients compared with the unvaccinated NSTEMI group, Galectin-3 levels remained comparable among all groups. No significant differences in Galectin-3 levels were observed according to vaccination status or vaccine type. Conclusions: In this exploratory cohort of NSTEMI patients, serum Galectin-3 levels did not differ significantly according to COVID-19 vaccination status or vaccine type. These findings suggest no detectable association between vaccination history and Galectin-3 levels in the study population. Larger prospective studies with longitudinal follow-up are needed to confirm these observations.
- 7 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5312
Open AccessThe Effect of COVID-19 Vaccines on Chronic Inflammatory Remodeling in NSTEMI Patients: A Galectin-3-Based Single-Center Study
Background: This study evaluated the potential effects of different COVID-19 vaccine platforms (mRNA and inactivated) on acute coronary syndrome (ACS) through Galectin-3, a biomarker of chronic inflammation and fibrosis. It aimed to compare serum Galectin-3 levels among NSTEMI patients according to COVID-19 vaccination status and vaccine type. Methods: A total of 75 patients with NSTEMI were prospectively enrolled and categorized into three groups: inactivated vaccine recipients (n = 25), mRNA vaccine recipients (n = 25), and unvaccinated controls (n = 25). Serum Galectin-3 levels were measured to assess chronic inflammatory status. Additionally, markers of acute myocardial injury and inflammatory response were analyzed. Results: Galectin-3 levels were similar across the inactivated vaccine, mRNA vaccine, and unvaccinated NSTEMI group, with no statistically significant difference observed (p = 0.481). Although troponin I levels and acute inflammatory cell burden were higher in vaccinated patients compared with the unvaccinated NSTEMI group, Galectin-3 levels remained comparable among all groups. No significant differences in Galectin-3 levels were observed according to vaccination status or vaccine type. Conclusions: In this exploratory cohort of NSTEMI patients, serum Galectin-3 levels did not differ significantly according to COVID-19 vaccination status or vaccine type. These findings suggest no detectable association between vaccination history and Galectin-3 levels in the study population. Larger prospective studies with longitudinal follow-up are needed to confirm these observations.
- Open Access
- 30 November 2025
- Published by Ordu University in MIDDLE BLACK SEA JOURNAL OF HEALTH SCIENCE
- Vol. 11 (4) , 370-382
Diagnostic Value of Signal Peptide-CUB-EGF Domain-Containing Protein 1 (SCUBE-1), Intestinal Fatty Acid Binding Protein (iFABP), and Ischemia-Modified Albumin (IMA) in Mechanical Bowel Obstruction
Objective: Mechanical bowel obstruction (MBO) is a common surgical pathology among patients presenting to the emergency department with abdominal pain worldwide and is associated with high morbidity rates. Delays in diagnosis and surgical intervention decisions can lead to severe complications such as bowel ischemia, adversely affecting patient survival rates. Therefore, reliable biomarkers are needed for the early diagnosis of MBO and in the surgical decision-making process. This study aimed to evaluate the diagnostic value of i-FABP, SCUBE-1, and IMA in predicting strangulation and bowel ischemia. Method: This prospective study was conducted at a tertiary hospital between January 2020 and January 2022. The study included 44 patients diagnosed with mechanical bowel obstruction who presented to the emergency department with abdominal pain, along with a control group of 40 healthy individuals. Patients were classified into two groups based on the need for surgical intervention: those who underwent surgery (Group B) and those who did not (Group A). Venous blood samples were collected, and the levels of i-FABP, SCUBE-1, and IMA were measured using the ELISA method. Data were analyzed using SPSS software. Results: The mean i-FABP levels were 56.4±11.5 ng/mL in Group A, 62.3±10.1 ng/mL in Group B, and 41.9±12.2 ng/mL in the control group, with a statistically significant difference observed between the groups (p
- 30 November 2025
- Published by Ordu University in MIDDLE BLACK SEA JOURNAL OF HEALTH SCIENCE
- Vol. 11 (4) , 370-382
Open AccessDiagnostic Value of Signal Peptide-CUB-EGF Domain-Containing Protein 1 (SCUBE-1), Intestinal Fatty Acid Binding Protein (iFABP), and Ischemia-Modified Albumin (IMA) in Mechanical Bowel Obstruction
Objective: Mechanical bowel obstruction (MBO) is a common surgical pathology among patients presenting to the emergency department with abdominal pain worldwide and is associated with high morbidity rates. Delays in diagnosis and surgical intervention decisions can lead to severe complications such as bowel ischemia, adversely affecting patient survival rates. Therefore, reliable biomarkers are needed for the early diagnosis of MBO and in the surgical decision-making process. This study aimed to evaluate the diagnostic value of i-FABP, SCUBE-1, and IMA in predicting strangulation and bowel ischemia. Method: This prospective study was conducted at a tertiary hospital between January 2020 and January 2022. The study included 44 patients diagnosed with mechanical bowel obstruction who presented to the emergency department with abdominal pain, along with a control group of 40 healthy individuals. Patients were classified into two groups based on the need for surgical intervention: those who underwent surgery (Group B) and those who did not (Group A). Venous blood samples were collected, and the levels of i-FABP, SCUBE-1, and IMA were measured using the ELISA method. Data were analyzed using SPSS software. Results: The mean i-FABP levels were 56.4±11.5 ng/mL in Group A, 62.3±10.1 ng/mL in Group B, and 41.9±12.2 ng/mL in the control group, with a statistically significant difference observed between the groups (p
- Open Access
- 21 November 2025
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 51 (3) , 405-410
Serum fatty acid synthase and GLP-1 levels in prostate cancer and benign prostatic hyperplasia
Objectives: This study aimed to investigate the differences in serum fatty acid synthase (FASN) and glucagon-like peptide-1 (GLP-1) levels among patients diagnosed with prostate cancer, benign prostatic hyperplasia (BPH), and healthy controls. Methods: A total of 60 male patients and 28 healthy male subjects were included in the study. Based on biopsy results, the patients were divided into two groups: prostate cancer (n=30) and BPH (n=30). Results: The mean FASN level was 6.71 ± 0.81 ng/mL in the prostate cancer group, 3.84 ± 0.21 ng/mL in the BPH group, and 3.57 ± 0.29 ng/mL in the control group. There was no statistically significant difference in FASN levels between the BPH and control groups (p>0.05). However, FASN levels were significantly higher in the prostate cancer group compared to both the control and BPH groups (p<0.001). The mean GLP-1 level was 9.69 ± 0.65 pmol/L in the prostate cancer group, 11.40 ± 0.77 pmol/L in the BPH group, and 7.03 ± 0.62 pmol/L in the control group. Compared to the control group, GLP-1 levels were significantly elevated in both the BPH and prostate cancer groups (p0.05). Conclusions: Our findings suggest that FASN and GLP-1 levels may contribute to the diagnostic accuracy of prostate diseases when used in conjunction with PSA and its derivatives.
- 21 November 2025
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 51 (3) , 405-410
Open AccessSerum fatty acid synthase and GLP-1 levels in prostate cancer and benign prostatic hyperplasia
Objectives: This study aimed to investigate the differences in serum fatty acid synthase (FASN) and glucagon-like peptide-1 (GLP-1) levels among patients diagnosed with prostate cancer, benign prostatic hyperplasia (BPH), and healthy controls. Methods: A total of 60 male patients and 28 healthy male subjects were included in the study. Based on biopsy results, the patients were divided into two groups: prostate cancer (n=30) and BPH (n=30). Results: The mean FASN level was 6.71 ± 0.81 ng/mL in the prostate cancer group, 3.84 ± 0.21 ng/mL in the BPH group, and 3.57 ± 0.29 ng/mL in the control group. There was no statistically significant difference in FASN levels between the BPH and control groups (p>0.05). However, FASN levels were significantly higher in the prostate cancer group compared to both the control and BPH groups (p<0.001). The mean GLP-1 level was 9.69 ± 0.65 pmol/L in the prostate cancer group, 11.40 ± 0.77 pmol/L in the BPH group, and 7.03 ± 0.62 pmol/L in the control group. Compared to the control group, GLP-1 levels were significantly elevated in both the BPH and prostate cancer groups (p0.05). Conclusions: Our findings suggest that FASN and GLP-1 levels may contribute to the diagnostic accuracy of prostate diseases when used in conjunction with PSA and its derivatives.
- Open Access
- 14 October 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (5) , 1311-1318
The importance of Galectin-3 in the diagnosis of childhood acute appendicitis
Background/aim: Acute appendicitis (AA) is a frequent indication for emergency surgery in children; accurate diagnosis is essential to prevent complications. We examined whether serum Galectin-3 is associated with pediatric AA and quantified its diagnostic performance relative to routine inflammatory markers. Materials and methods: This prospective, single-center study was conducted in a tertiary emergency department between July 1, 2023, and January 31, 2024. Children younger than 18 years with pathologically confirmed AA were enrolled as cases; age-compatible healthy volunteers served as controls. Venous blood was obtained at presentation before any therapeutic intervention. Galectin-3 concentrations were quantified using a commercial enzyme-linked immunosorbent assay. The primary endpoint was the ability of Galectin-3 to discriminate AA from controls. Receiver operating characteristic analysis was performed to assess discrimination, yielding area under the curve estimates with 95% confidence intervals (CIs); sensitivity and specificity were quantified at prespecified thresholds. Results: Seventy-four children were analyzed (AA group n = 47; control group n = 27). Compared with controls, the AA group had higher Galectin-3, leukocyte and neutrophil counts, C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lower lymphocyte counts and platelet-to-neutrophil ratio (PNR) (all p < 0.05). Galectin-3 yielded an area under the curve (AUC) value of 0.680 (95% CI, 0.55–0.81). At a threshold of >130.71 pg/mL, sensitivity was 91.49% and specificity was 33.33%; at >115.71 pg/mL, sensitivity was 100.00% with the same specificity; at >254.90 pg/mL, specificity was 92.30% with sensitivity 29.79%. Conclusion: Serum Galectin-3 is elevated in pediatric AA and affords moderate discrimination. Owing to limited specificity at pragmatic cut-offs, Galectin-3 alone is insufficient as a standalone test; however, it may serve as a rule-out adjunct within multimodal pathways. External validation in larger, multicenter cohorts is warranted.
- 14 October 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (5) , 1311-1318
Open AccessThe importance of Galectin-3 in the diagnosis of childhood acute appendicitis
Background/aim: Acute appendicitis (AA) is a frequent indication for emergency surgery in children; accurate diagnosis is essential to prevent complications. We examined whether serum Galectin-3 is associated with pediatric AA and quantified its diagnostic performance relative to routine inflammatory markers. Materials and methods: This prospective, single-center study was conducted in a tertiary emergency department between July 1, 2023, and January 31, 2024. Children younger than 18 years with pathologically confirmed AA were enrolled as cases; age-compatible healthy volunteers served as controls. Venous blood was obtained at presentation before any therapeutic intervention. Galectin-3 concentrations were quantified using a commercial enzyme-linked immunosorbent assay. The primary endpoint was the ability of Galectin-3 to discriminate AA from controls. Receiver operating characteristic analysis was performed to assess discrimination, yielding area under the curve estimates with 95% confidence intervals (CIs); sensitivity and specificity were quantified at prespecified thresholds. Results: Seventy-four children were analyzed (AA group n = 47; control group n = 27). Compared with controls, the AA group had higher Galectin-3, leukocyte and neutrophil counts, C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lower lymphocyte counts and platelet-to-neutrophil ratio (PNR) (all p < 0.05). Galectin-3 yielded an area under the curve (AUC) value of 0.680 (95% CI, 0.55–0.81). At a threshold of >130.71 pg/mL, sensitivity was 91.49% and specificity was 33.33%; at >115.71 pg/mL, sensitivity was 100.00% with the same specificity; at >254.90 pg/mL, specificity was 92.30% with sensitivity 29.79%. Conclusion: Serum Galectin-3 is elevated in pediatric AA and affords moderate discrimination. Owing to limited specificity at pragmatic cut-offs, Galectin-3 alone is insufficient as a standalone test; however, it may serve as a rule-out adjunct within multimodal pathways. External validation in larger, multicenter cohorts is warranted.
- 31 August 2025
- Published by Ordu University in ODÜ Tıp Dergisi
- Vol. 12 (2) , 43-54
Evaluation of the Gastroprotective Effects of Hazelnut Oil Against Ethanol-Induced Gastric Mucosal Injury in Rats
This study aimed to investigate the gastroprotective effects of hazelnut oil against ethanol-induced gastric mucosal injury in rats by macroscopic and histopathological evaluations. Thirty-five male Wistar rats (180–220 g) were randomly divided into five groups (n=7): Control (saline), Ethanol (75% ethanol, 5 mL/kg), Hazelnut Oil-Low Dose (HO-L, 2.5 mL/kg hazelnut oil + ethanol), Hazelnut Oil-High Dose (HO-H, 5 mL/kg hazelnut oil + ethanol), and Ranitidine (50 mg/kg + ethanol). Treatments were administered orally for 7 days, followed by ethanol. Ulcer area, inhibition rate, and histopathological scores (inflammation, edema, epithelial damage, hemorrhage) were evaluated. Statistical analysis was performed using one-way ANOVA and Kruskal-Wallis tests. Ethanol induced significant gastric injury, while HO-L, HO-H, and Ranitidine groups showed significantly reduced ulcer areas (P < 0.001) and histopathological scores (P < 0.005). The highest inhibition was observed in the Ranitidine group (95%), followed by HO-H (78%) and HO-L (39%). Hazelnut oil exerts a dose-dependent protective effect against ethanol-induced gastric damage, likely due to its oleic acid and vitamin E content. These findings suggest hazelnut oil may serve as a natural alternative in the prevention of gastric ulcers.
- 31 August 2025
- Published by Ordu University in ODÜ Tıp Dergisi
- Vol. 12 (2) , 43-54
Evaluation of the Gastroprotective Effects of Hazelnut Oil Against Ethanol-Induced Gastric Mucosal Injury in Rats
This study aimed to investigate the gastroprotective effects of hazelnut oil against ethanol-induced gastric mucosal injury in rats by macroscopic and histopathological evaluations. Thirty-five male Wistar rats (180–220 g) were randomly divided into five groups (n=7): Control (saline), Ethanol (75% ethanol, 5 mL/kg), Hazelnut Oil-Low Dose (HO-L, 2.5 mL/kg hazelnut oil + ethanol), Hazelnut Oil-High Dose (HO-H, 5 mL/kg hazelnut oil + ethanol), and Ranitidine (50 mg/kg + ethanol). Treatments were administered orally for 7 days, followed by ethanol. Ulcer area, inhibition rate, and histopathological scores (inflammation, edema, epithelial damage, hemorrhage) were evaluated. Statistical analysis was performed using one-way ANOVA and Kruskal-Wallis tests. Ethanol induced significant gastric injury, while HO-L, HO-H, and Ranitidine groups showed significantly reduced ulcer areas (P < 0.001) and histopathological scores (P < 0.005). The highest inhibition was observed in the Ranitidine group (95%), followed by HO-H (78%) and HO-L (39%). Hazelnut oil exerts a dose-dependent protective effect against ethanol-induced gastric damage, likely due to its oleic acid and vitamin E content. These findings suggest hazelnut oil may serve as a natural alternative in the prevention of gastric ulcers.
- 26 July 2025
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 64 (7) , e70063
Tr‐KIT Downstream Regulation by YY1 and NFYA Transcription Factors Knockdown in Prostate Cancer Cells
Background: Prostate cancer is a common and deadly cancer among men and has been the subject of many patients in its diagnosis and treatment. Imatinib, a tyrosine kinase inhibitor, can slow tumor formation by targeting c‐KIT, an oncogenic receptor tyrosine kinase protein over‐expressed in PCa cases. However, Imatinib has no effect on tr‐KIT, a truncated form of c‐KIT, which is over‐expressed in PCa and is associated with neoplastic transformation. In this study, it is aimed to answer whether the anti‐proliferative efficacy of Imatinib on PCa cells could be enhanced by inhibition of tr‐KIT specific transcription factors.Methods and Results: For this purpose, gene expression analysis and cell viability assays were performed in LNCaP prostate cancer cells to investigate the effects of inhibition of transcription factors controlling tr‐KIT expression (YY1 and NFYA) in combination with Imatinib administration. As a result, YY1 and NFYA were identified as tr‐KIT‐specific transcription factors and found that their knockdown increased the effectiveness of Imatinib mesylate treatment on LNCaP cells. The study also analyzed the gene expression changes of c‐KIT, FYN, PLCγ1, and SAM68 genes and found that SAM68 expression decreased with NFYA and YY1 knockdown, suggesting the existence of other unknown mediators in the tr‐KIT pathway.Conclusions: All in all, this study demonstrates that tr‐KIT may be a potential pharmacological target for prostate cancer treatment and that inhibition of the transcription factors YY1 and NFYA may enhance the efficacy of Imatinib. SAM68 was found to be the most affected protein by the treatments, guiding future research.
- 26 July 2025
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 64 (7) , e70063
Tr‐KIT Downstream Regulation by YY1 and NFYA Transcription Factors Knockdown in Prostate Cancer Cells
Background: Prostate cancer is a common and deadly cancer among men and has been the subject of many patients in its diagnosis and treatment. Imatinib, a tyrosine kinase inhibitor, can slow tumor formation by targeting c‐KIT, an oncogenic receptor tyrosine kinase protein over‐expressed in PCa cases. However, Imatinib has no effect on tr‐KIT, a truncated form of c‐KIT, which is over‐expressed in PCa and is associated with neoplastic transformation. In this study, it is aimed to answer whether the anti‐proliferative efficacy of Imatinib on PCa cells could be enhanced by inhibition of tr‐KIT specific transcription factors.Methods and Results: For this purpose, gene expression analysis and cell viability assays were performed in LNCaP prostate cancer cells to investigate the effects of inhibition of transcription factors controlling tr‐KIT expression (YY1 and NFYA) in combination with Imatinib administration. As a result, YY1 and NFYA were identified as tr‐KIT‐specific transcription factors and found that their knockdown increased the effectiveness of Imatinib mesylate treatment on LNCaP cells. The study also analyzed the gene expression changes of c‐KIT, FYN, PLCγ1, and SAM68 genes and found that SAM68 expression decreased with NFYA and YY1 knockdown, suggesting the existence of other unknown mediators in the tr‐KIT pathway.Conclusions: All in all, this study demonstrates that tr‐KIT may be a potential pharmacological target for prostate cancer treatment and that inhibition of the transcription factors YY1 and NFYA may enhance the efficacy of Imatinib. SAM68 was found to be the most affected protein by the treatments, guiding future research.
- Open Access
- 30 December 2024
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 45 (4) , 636-647
Evaluation of Irisin Levels in Cancer Anorexia Cachexia Syndrome and the Relationship between Nutrition Education and Quality of Life
This study examines the effects of nutritional education given to individuals diagnosed with cancer anorexia cachexia syndrome (CACS) on serum irisin levels, cachectic factors, proinflammatory cytokines, quality of life scale results, and anthropometric and routine biochemical parameters. Forty-one patients diagnosed with CACS were randomly divided into two groups, experimental and control. Nutrition education was given for 12 weeks to the patients in the experimental group (n=23), while those in the control group (n=18) were not subjected to any intervention. All participants’ serum irisin, proteolysis-inducing factor, zinc-α-2 glycoprotein, interleukin-6, tumor necrosis factor-α, routine biochemical parameters, and body weight were measured at the beginning and end of the study. The patients were also evaluated in terms of 24-hour recall food intake, body mass index, and quality of life scale values. No significant differences were observed at baseline between the experimental and control groups in terms of quality of life scale values, cachectic factors, inflammatory cytokines, or irisin levels. However, at the end of the study, hemoglobin levels were higher in the experimental group than in the control group. Energy and nutrient intakes were similar between the groups initially, but were higher in the experimental group at the end of the study. Nutrition education did not significantly alter the quality of life scale, BMI, or biochemical parameters. However, education yielded the expected increase in nutrient intake in the experimental group.
- 30 December 2024
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 45 (4) , 636-647
Open AccessEvaluation of Irisin Levels in Cancer Anorexia Cachexia Syndrome and the Relationship between Nutrition Education and Quality of Life
This study examines the effects of nutritional education given to individuals diagnosed with cancer anorexia cachexia syndrome (CACS) on serum irisin levels, cachectic factors, proinflammatory cytokines, quality of life scale results, and anthropometric and routine biochemical parameters. Forty-one patients diagnosed with CACS were randomly divided into two groups, experimental and control. Nutrition education was given for 12 weeks to the patients in the experimental group (n=23), while those in the control group (n=18) were not subjected to any intervention. All participants’ serum irisin, proteolysis-inducing factor, zinc-α-2 glycoprotein, interleukin-6, tumor necrosis factor-α, routine biochemical parameters, and body weight were measured at the beginning and end of the study. The patients were also evaluated in terms of 24-hour recall food intake, body mass index, and quality of life scale values. No significant differences were observed at baseline between the experimental and control groups in terms of quality of life scale values, cachectic factors, inflammatory cytokines, or irisin levels. However, at the end of the study, hemoglobin levels were higher in the experimental group than in the control group. Energy and nutrient intakes were similar between the groups initially, but were higher in the experimental group at the end of the study. Nutrition education did not significantly alter the quality of life scale, BMI, or biochemical parameters. However, education yielded the expected increase in nutrient intake in the experimental group.
- Open Access
- 29 September 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (12) , 2723-2734
Non‐alcoholic fatty liver disease: The importance of physical activity and nutrition education—A randomized controlled study
Background and Aim: Non‐alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess fat in the liver, causing liver cell damage, increased inflammation, and weight gain. Despite its high prevalence, diagnosis and follow‐up of the disease is difficult. Irisin, a slimming myokine produced in response to physical activity (PA), exhibits anti‐inflammatory and anti‐obesity effects. This study aimed to investigate changes in irisin levels, inflammation markers (tumor necrosis factor‐α [TNF‐α] and interleukin‐6 [IL‐6]), and myeloid differentiation factor‐2 (MD2) levels in NAFLD, as well as anthropometric and routine biochemical parameters, by providing PA recommendations and nutrition education (NE) to individuals diagnosed with NAFLD over a period of 12 weeks. Methods: The study included 62 patients diagnosed with NAFLD who did not use alcohol. They were divided into groups: PA, NE, both (NE + PA), and untreated (control) patients. Patients receiving NE were provided with 1‐h NE sessions every 4 weeks for 12 weeks, and their personal information, nutritional status, 24‐h retrospective food consumption record, and anthropometric measurements were recorded at the beginning (day 0) and end (week 12) of the study. The PA group was recommended aerobic walking for 30 min, 5 days a week. At the beginning (day 0) and end (week 12) of the study, patients' anthropometric and routine biochemical tests were conducted, and irisin, MD2, TNF‐α, and IL‐6 levels were measured using the ELISA method. Results: All groups were similar in demographic characteristics and dietary habits. After 12 weeks, there were no significant differences in biochemical parameters among the groups. Glucose levels increased in the untreated group but decreased in the PA and PA + NE groups compared to baseline, with a significant decrease in the PA group. Insulin levels significantly decreased in the NE group. The PA + NE group showed decreased aspartate aminotransferase (AST), gamma‐glutamyl transferase, alkaline phosphatase, total cholesterol, low‐density lipoprotein, and triglyceride levels and significant decrease in ALT levels. AST decreased significantly in the PA group while high‐density lipoprotein increased significantly. There were no statistically significant differences between the groups in irisin, MD2, IL‐6, and TNF‐α levels. After 12 weeks, irisin levels significantly increased in nutrition and PA groups except the untreated group. There were no statistically significant differences in IL‐6 and MD2 levels compared with baseline after 12 weeks. PA recommendations alone were not effective in observing significant changes in anthropometric measurements in individuals with NAFLD. It was detected that only nutritional recommendations provided a significant decrease in body fat ratio but were insufficient for the change in other anthropometric measurements. In the group where NE and PA were recommended together, a significant decrease in anthropometric measurements was found. The NE group significantly reduced their energy and carbohydrates (%EI) intake after 12 weeks of intervention compared with the baseline. Conclusion: NE and PA recommendations led to improvements in liver‐related biochemical parameters and significant reductions in anthropometric measurements among individuals with NAFLD. Moreover, patients receiving NE experienced a decrease in energy and carbohydrates intake as a percentage of total energy intake (%EI). Increased irisin levels in NE, PA, and NE + PA groups may have contributed to the decrease in body fat percentage.
- 29 September 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (12) , 2723-2734
Open AccessNon‐alcoholic fatty liver disease: The importance of physical activity and nutrition education—A randomized controlled study
Background and Aim: Non‐alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess fat in the liver, causing liver cell damage, increased inflammation, and weight gain. Despite its high prevalence, diagnosis and follow‐up of the disease is difficult. Irisin, a slimming myokine produced in response to physical activity (PA), exhibits anti‐inflammatory and anti‐obesity effects. This study aimed to investigate changes in irisin levels, inflammation markers (tumor necrosis factor‐α [TNF‐α] and interleukin‐6 [IL‐6]), and myeloid differentiation factor‐2 (MD2) levels in NAFLD, as well as anthropometric and routine biochemical parameters, by providing PA recommendations and nutrition education (NE) to individuals diagnosed with NAFLD over a period of 12 weeks. Methods: The study included 62 patients diagnosed with NAFLD who did not use alcohol. They were divided into groups: PA, NE, both (NE + PA), and untreated (control) patients. Patients receiving NE were provided with 1‐h NE sessions every 4 weeks for 12 weeks, and their personal information, nutritional status, 24‐h retrospective food consumption record, and anthropometric measurements were recorded at the beginning (day 0) and end (week 12) of the study. The PA group was recommended aerobic walking for 30 min, 5 days a week. At the beginning (day 0) and end (week 12) of the study, patients' anthropometric and routine biochemical tests were conducted, and irisin, MD2, TNF‐α, and IL‐6 levels were measured using the ELISA method. Results: All groups were similar in demographic characteristics and dietary habits. After 12 weeks, there were no significant differences in biochemical parameters among the groups. Glucose levels increased in the untreated group but decreased in the PA and PA + NE groups compared to baseline, with a significant decrease in the PA group. Insulin levels significantly decreased in the NE group. The PA + NE group showed decreased aspartate aminotransferase (AST), gamma‐glutamyl transferase, alkaline phosphatase, total cholesterol, low‐density lipoprotein, and triglyceride levels and significant decrease in ALT levels. AST decreased significantly in the PA group while high‐density lipoprotein increased significantly. There were no statistically significant differences between the groups in irisin, MD2, IL‐6, and TNF‐α levels. After 12 weeks, irisin levels significantly increased in nutrition and PA groups except the untreated group. There were no statistically significant differences in IL‐6 and MD2 levels compared with baseline after 12 weeks. PA recommendations alone were not effective in observing significant changes in anthropometric measurements in individuals with NAFLD. It was detected that only nutritional recommendations provided a significant decrease in body fat ratio but were insufficient for the change in other anthropometric measurements. In the group where NE and PA were recommended together, a significant decrease in anthropometric measurements was found. The NE group significantly reduced their energy and carbohydrates (%EI) intake after 12 weeks of intervention compared with the baseline. Conclusion: NE and PA recommendations led to improvements in liver‐related biochemical parameters and significant reductions in anthropometric measurements among individuals with NAFLD. Moreover, patients receiving NE experienced a decrease in energy and carbohydrates intake as a percentage of total energy intake (%EI). Increased irisin levels in NE, PA, and NE + PA groups may have contributed to the decrease in body fat percentage.
- 29 December 2022
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 20 (3) , 131-135
Interference in the measurement of Hemoglobin A1c: Presence of Hemoglobin D
Olgumuzda HbA1c ölçümü yüksek performanslı sıvı kromatografisi (HPLC) yöntemiyle gerçekleştirildi ve sonuç %3.5 (14.75 mmol/mol) olarak ölçüldü. HbA1c sonucunun hastanın diğer klinik değerleriyle uyumsuz olması nedeniyle, aynı örnek cihazın varyant modunda çalışıldı ve Hb varyantı uyarısı alındı. Örneğin varyant analizi sonucunda HbD varyantı varlığı tespit edildi ve HbA1c sonucu %5.1 (32 mmol/mol) olarak rapor edildi. Hastanın kliniğine uygun olmayan düşük HbA1c değerinin varlığında Hb varyant varlığı düşünülerek örnek tekrar incelenmelidir.
- 29 December 2022
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 20 (3) , 131-135
Interference in the measurement of Hemoglobin A1c: Presence of Hemoglobin D
Olgumuzda HbA1c ölçümü yüksek performanslı sıvı kromatografisi (HPLC) yöntemiyle gerçekleştirildi ve sonuç %3.5 (14.75 mmol/mol) olarak ölçüldü. HbA1c sonucunun hastanın diğer klinik değerleriyle uyumsuz olması nedeniyle, aynı örnek cihazın varyant modunda çalışıldı ve Hb varyantı uyarısı alındı. Örneğin varyant analizi sonucunda HbD varyantı varlığı tespit edildi ve HbA1c sonucu %5.1 (32 mmol/mol) olarak rapor edildi. Hastanın kliniğine uygun olmayan düşük HbA1c değerinin varlığında Hb varyant varlığı düşünülerek örnek tekrar incelenmelidir.